Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to improve ...

Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded ...

Arrowhead Pharmaceuticals, Inc. today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement ...

New research from the University of Ottawa sees mRNA and RNAi-based therapies delivered in single treatment, paving way for treatment of cancer, cardiovascular diseases.

The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.

We’ll also explore the company’s innovative approach to treating cancer, particularly those driven by KRAS mutations, and why Prof. Peled’s addition could be a game-changer. The recent appointment of ...

Arrowhead (ARWR) announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference, or ...

With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes have been awarded to the ...

Researchers at the University of Ottawa have figured out how to use mRNA and RNAI-based treatments to treat complex illnesses ...

Major findings on the inner workings of a brittle star's ability to reversibly control the pliability of its tissues will ...

CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the ...

One of their distinctive abilities is detaching a portion of the body to escape from predators. A few species of brittle ...